Four plans, and the maths holds
The weight-loss program page prices a monthly plan and a quarterly plan for each of the two drugs. The quarterly plans are stated as a total for the quarter, and dividing each by three gives a per-month figure. We have stored both forms, with the arithmetic shown in each qualifier, because a prepaid total and a monthly rate are different commitments and a reader should not have to do the division to see that.
That is more than most of this roster offers. A seller that prints only a starting figure leaves the term invisible; this one prints the term and the total and lets the two be checked against each other.
The page also prices a separate custom weight-loss kit, and the site sells NAD+ and sermorelin lanes alongside. Those are outside the two GLP-1 drugs and are not in our record.
Two starting rates for one program
The mega-menu that renders at the top of the same page advertises the weight-loss program at one starting rate. The page heading, a few hundred pixels below it, advertises it at a higher one. Both are laid-out visible text in a single fetch, and neither is a stale cache: the requested path equalled the effective path, and a nonsense path on the same host returned a not-found status in the same run.
Which one binds is not stated anywhere. We record the page figures, because they are the ones attached to named plans, and the menu figure rides in the first row's qualifier.
The warning letter, and what it says
FDA wrote to this company in September 2025. The letter is addressed to the founder by name and title, states that the agency reviewed the website in August 2025, and finds the claims made about its compounded semaglutide and tirzepatide false or misleading under the misbranding provisions of the Act.
Twenty-one of the one hundred and fifty-eight sellers here carry an FDA warning letter. A warning letter is disclosed on this site and it never moves a score or a ranking position; most of these letters concern marketing and labelling rather than the contents of a vial, and this one is explicitly about website claims.
It is worth saying how we found it, because the obvious method fails. Searching FDA's record by this seller's domain returns nothing at all. Letters are indexed by entity name and by the name a company does business as, so a search keyed to a website clears every seller it is pointed at and produces a roster that looks clean.
The rest of the disclosure
The founder is named as a triple board-certified physician on the priced page, and the affiliated medical group is named separately in the Terms. Fifty of the one hundred and fifty-eight sellers here name an individual clinician.
No compounding pharmacy is named. One hundred and twenty-six of the one hundred and fifty-eight sellers here name none. No service-area list exists; one hundred and fifteen of the one hundred and fifty-eight sellers here publish none. The membership question goes unanswered on a page that prices five things; sixty-four of the one hundred and fifty-eight sellers here leave it unanswered too.
One host note, because it is the kind of thing that manufactures a false result: a nonsense path on this domain returns a correct not-found status with nearly six thousand characters of navigation and footer text in the body. A check that reads the size of a response, or asks whether the body looks like a real page, would verify any address you invented here. Only the status code separates them.
Healthon's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $189/moas low as, on a monthly plan; the site-wide weight-loss menu on the same page advertises the program as starting at $155/mo | September 2026source |
| Semaglutide (compounded) | $183/moper month derived from the seller’s own published quarterly price of $549 on a 3-month plan ($549 divided by 3 is $183) | September 2026source |
| Tirzepatide (compounded) | $295/moas low as, on a monthly plan | September 2026source |
| Tirzepatide (compounded) | $279/moper month derived from the seller’s own published quarterly price of $837 on a 3-month plan ($837 divided by 3 is $279) | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Healthon's current price →Good fit if
- Readers who want the prepaid quarterly total printed beside the monthly rate, and who will check that it divides.
- Buyers who want a named, credentialled physician attached to the business rather than a reference to a network.
- People comparing a monthly commitment against a three-month one for both drugs on one page.
Look elsewhere if
- Anyone who wants one advertised starting rate. The menu and the page heading state two, in the same reading.
- Readers for whom an FDA warning letter about website claims is disqualifying.
- Buyers who want the compounding pharmacy named.
- People who need to know whether the service reaches their state, or whether a membership fee applies.
How this review was verified
- Re-read the weight-loss program page and the terms and conditions on 6 September 2026 rather than carrying figures across from the research file, which recorded the two conflicting starting rates but none of the four plan figures.
- Compared the requested path to the effective path on every fetch and ran a nonsense path against this host in the same run. It returned a not-found status with nearly six thousand characters of shell text, which is why nothing here was judged by response size.
- Divided each published quarterly total by three and recorded the result in the price qualifier rather than presenting a derived figure as if the seller had printed it.
- Screened the entity name and the brand name against FDA's live warning-letter record, with a known letter as a positive control and a nonsense string as a negative control in the same pass. A domain-keyed search of the same record returns nothing for this seller, which is why the search was keyed to names.
- Re-fetched the warning letter itself and confirmed its title names this exact entity, number and date, against a minted nonsense letter path on fda.gov in the same run that returned a not-found status.
- Untitled FDA letters are published separately and were not searched, so what this establishes is a warning letter found, and for the sellers with none, no warning letter found.